Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSV mRNA vaccine (RNACure Biopharma)
- Development stage
- Preclinical
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The HSV mRNA vaccine is an investigational messenger RNA (mRNA) based vaccine being developed by RNACure Biopharma for the prevention or treatment of Herpes Simplex Virus (HSV) infections. Utilizing RNACure's proprietary mRNA platform, the vaccine is designed to encode specific HSV viral antigens. Upon administration, the mRNA is delivered into host cells where it is translated into viral proteins. these proteins are then presented to the immune system to elicit a robust and targeted immune response, including the production of neutralizing antibodies and the activation of T-cells. This approach aims to provide protective immunity against HSV-1 and/or HSV-2, potentially reducing the incidence of oral and genital herpes outbreaks and viral shedding.
- Other names
- Herpes Simplex Virus mRNA vaccineHSV mRNA vaccineRNACure HSV vaccine
02
Targets
Herpes simplex virus surface glycoproteins
Beyond the preview
Go deeper on HSV mRNA vaccine (RNACure Biopharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSV mRNA vaccine (RNACure Biopharma).